Literature DB >> 15368498

Thioredoxin interacting protein in Dutch families with familial combined hyperlipidemia.

Gerly M van der Vleuten1, Anneke Hijmans, Leo A J Kluijtmans, Henk J Blom, Anton F H Stalenhoef, Jacqueline de Graaf.   

Abstract

Familial combined hyperlipidemia (FCH), characterized by multiple lipoprotein phenotypes, is the most common hereditary lipid disorder in humans. A mutant mouse strain, HcB-19, with similar biochemical features as FCH patients, has recently been identified. The mutation causing the FCH phenotype in these mice is located in the thioredoxin interacting protein (TXNIP) gene. The TXNIP gene in mice is located on chromosome 3F2.2, which is syntenic to chromosome 1q21 in humans, a region where several groups have positioned a locus for FCH. To evaluate the potential role of TXNIP in the FCH phenotype in humans, we analyzed the coding region, 5' UTR and introns of the TXNIP gene by direct sequencing in 10 well-defined patients with FCH and 5 healthy controls. We did not find any sequence variants in these regions of the TXNIP gene in patients with FCH. Our results suggest that different genes are involved in the FCH phenotype in humans compared to mice. We conclude that in our Dutch FCH patients, the TXNIP gene, based on its intronic, exonic, and 5' UTR sequences, is not involved as a major contributor to the FCH phenotype. This article contains supplementary material, which may be viewed at the American Journal of Medical Genetics website at http://www.interscience.wiley.com/jpages/0148-7299/suppmat/index.html. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15368498     DOI: 10.1002/ajmg.a.30036

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  7 in total

Review 1.  The genetics of familial combined hyperlipidaemia.

Authors:  Martijn C G J Brouwers; Marleen M J van Greevenbroek; Coen D A Stehouwer; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Nat Rev Endocrinol       Date:  2012-02-14       Impact factor: 43.330

Review 2.  Genetic lipoprotein disorders and coronary atherosclerosis.

Authors:  Mahmoud Alawadhi; George Thanassoulis; Michel Marcil; Jacques Genest
Journal:  Curr Atheroscler Rep       Date:  2005-05       Impact factor: 5.113

Review 3.  Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance.

Authors:  Samuel Lee; Soo Min Kim; Richard T Lee
Journal:  Antioxid Redox Signal       Date:  2012-06-26       Impact factor: 8.401

4.  Identification and validation of seven new loci showing differential DNA methylation related to serum lipid profile: an epigenome-wide approach. The REGICOR study.

Authors:  S Sayols-Baixeras; I Subirana; C Lluis-Ganella; F Civeira; J Roquer; A N Do; D Absher; A Cenarro; D Muñoz; C Soriano-Tárraga; J Jiménez-Conde; J M Ordovas; M Senti; S Aslibekyan; J Marrugat; D K Arnett; R Elosua
Journal:  Hum Mol Genet       Date:  2016-10-15       Impact factor: 6.150

5.  High glucose condition upregulated Txnip expression level in rat mesangial cells through ROS/MEK/MAPK pathway.

Authors:  Shaohong Fang; Yuhong Jin; Haixia Zheng; Junxia Yan; Yunxia Cui; Huimei Bi; Huijie Jia; Huishu Zhang; Yi Wang; Liying Na; Xu Gao; Hongbo Zhou
Journal:  Mol Cell Biochem       Date:  2010-10-19       Impact factor: 3.396

Review 6.  Thioredoxin-Interacting Protein in Cancer and Diabetes.

Authors:  Hiroshi Masutani
Journal:  Antioxid Redox Signal       Date:  2021-10-07       Impact factor: 7.468

7.  Thioredoxin binding protein (TBP)-2/Txnip and α-arrestin proteins in cancer and diabetes mellitus.

Authors:  Hiroshi Masutani; Eiji Yoshihara; So Masaki; Zhe Chen; Junji Yodoi
Journal:  J Clin Biochem Nutr       Date:  2011-10-26       Impact factor: 3.114

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.